imatinib mesylate has been researched along with Hyperglycemia, Postprandial in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Luvira, V; Pairojkul, C; Wannasri, T | 1 |
| Allard, NAE; Blijlevens, NMA; Boss, M; Gotthardt, M; Hopman, MTE; Janssen, L; Lobeek, D; Schirris, TJJ; Swaans, GJA; Timmers, S | 1 |
| Huang, X; Jiang, Q; Liu, J; Yu, L | 1 |
| Cardoso, HJ; Carvalho, TMA; Figueira, MI; Socorro, S; Vaz, CV | 1 |
| Hoopes, EM; Karp, J; Moore, DJ; Spaeth, JM; Stein, RW; Stocks, BT; Wilson, CS | 1 |
| Glynne, R; Herman, AE; Lau, J; Schmedt, C; Sutton, SE; Zhou, Q | 1 |
| Gur, S; Hellstrom, WJ; Kadowitz, PJ | 1 |
| Araki, E; Furukawa, N; Kawaguchi, T; Kikukawa, Y; Ono, K; Shimomura, T; Suzushima, H; Watanabe, Y | 1 |
| Elliman, S; Hägerkvist, R; Makeeva, N; Welsh, N | 1 |
9 other study(ies) available for imatinib mesylate and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Dramatic disappearance of hyperglycemia and abnormal neurologic symptoms after resection of duodenal gastrointestinal stromal tumor.
Topics: Aged; Duodenum; Female; Gastrointestinal Stromal Tumors; Humans; Hyperglycemia; Imatinib Mesylate; Paraneoplastic Syndromes | 2022 |
Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia.
Topics: Blood Glucose; Cardiovascular Diseases; Fluorodeoxyglucose F18; Glucose; Glycogen; Humans; Hyperglycemia; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Tyrosine Kinase Inhibitors | 2023 |
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cholesterol, LDL; Dasatinib; Female; Follow-Up Studies; Glucose; Humans; Hyperglycemia; Hypertriglyceridemia; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lipid Metabolism; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Young Adult | 2019 |
Tyrosine kinase inhibitor imatinib modulates the viability and apoptosis of castrate-resistant prostate cancer cells dependently on the glycolytic environment.
Topics: Apoptosis; Cell Proliferation; Glucose; Glycolysis; Humans; Hyperglycemia; Imatinib Mesylate; Lactic Acid; Male; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2019 |
B lymphocytes protect islet β cells in diabetes prone NOD mice treated with imatinib.
Topics: Animals; Autoimmunity; B-Lymphocytes; Cell Proliferation; Diabetes Mellitus, Type 1; Disease Models, Animal; Homeodomain Proteins; Hyperglycemia; Imatinib Mesylate; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Maf Transcription Factors, Large; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout | 2019 |
Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice.
Topics: Animals; Benzamides; Female; Hyperglycemia; Imatinib Mesylate; Mice; Mice, Inbred NOD; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2014 |
A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats.
Topics: Animals; Benzamides; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Hyperglycemia; Imatinib Mesylate; Impotence, Vasculogenic; Male; Penile Erection; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Sprague-Dawley | 2010 |
Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hyperglycemia; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Death; Cell Survival; Diabetes Mellitus, Experimental; Hyperglycemia; Imatinib Mesylate; Islets of Langerhans; Male; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Streptozocin | 2006 |